Homburger advises Santhera on successful reverse share split 

Homburger has provided legal counsel to Santhera Pharmaceuticals Holding (SIX: SANN “Santhera”) on its completion of a 10:1 reverse split of its shares. The reverse split, which was approved by shareholders on June 27, 2023, resulted in the listing and commencement of trading of the post-split shares on the SIX Swiss Exchange. 

The reverse share split was made possible by a recent rule change that simplified the process for Swiss public companies to undertake such transactions, effective from January 1, 2023. 

Under the reverse stock split, new shares were issued with a new International Securities Identification Number (ISIN), while the existing shares held prior to the split were canceled. Shareholders who wish to retain their voting rights are advised to ensure their re-registration in the Company’s share register for technical purposes. 

Santhera is a Swiss specialty pharmaceutical company that focuses on developing and commercializing innovative medicines for rare neuromuscular and pulmonary diseases with significant unmet medical needs. 

The Homburger team was led by Daniel Häusermann (corporate / m&a, capital markets, pictured) and included Stefan Oesterhelt (tax), Jasmin Künzle and Martin Cattaneo (both corporate / m&a, capital markets) as well as Eduard De Zordi and Philipp Klein (both capital markets).